XML 16 R55.htm IDEA: XBRL DOCUMENT
v2.4.0.8

SEGMENT AND GEOGRAPHIC INFORMATION - Net Sales and Profit by Reportable Segment (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2014 | Sep. 30, 2013 | Sep. 30, 2014 | Sep. 30, 2013
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | $ 229,719 | $ 213,246 |  | $ 676,129 | $ 615,445 |
Operating income | 17,727 | (31,141) | [1] | 38,857 | (27,775) | [1]
Intangible asset amortization | (2,995) | (3,036) | [1] | (9,013) | (9,660) | [1]
Operating Segments |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Operating income | 91,566 | 33,560 |  | 259,232 | 167,199 |
Operating Segments | U.S. Neurosurgery |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | 62,323 | 45,114 |  | 177,265 | 125,877 |
Operating income | 35,889 | 23,080 |  | 94,247 | 59,770 |
Operating Segments | U.S. Instruments |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | 39,853 | 43,004 |  | 116,078 | 121,900 |
Operating income | 12,416 | 13,713 |  | 34,728 | 35,963 |
Operating Segments | U.S. Extremities |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | 36,746 | 31,831 |  | 103,083 | 93,802 |
Operating income | 14,983 | 13,117 |  | 40,907 | 34,613 |
Operating Segments | U.S. Spine And Other [Member] |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | 42,015 | 47,408 |  | 128,168 | 134,889 |
Operating income | 13,108 | (31,043) |  | 39,801 | (4,844) |
Operating Segments | International |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Revenues | 48,782 | 45,889 |  | 151,535 | 138,977 |
Operating income | 15,170 | 14,693 |  | 49,549 | 41,697 |
Corporate, Non-Segment |  |  |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |  |  |
Operating income | $ (70,844) | $ (61,665) |  | $ (211,362) | $ (185,314) |
[1] | See Note 1 of these condensed consolidated financial statements for discussion of the impact of the change in accounting for the medical device excise tax.

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References No definition available. + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration